GLP-1 Weight Loss in Shreveport: Real Specialists, No Real Prices
Shreveport's 43.1% obesity rate, Louisiana's signed-but-unfunded Act 898, six clinics with zero published prices, and Ochsner LSU Health's endocrinology division.
43.1% of Shreveport adults have obesity (CDC PLACES 2025 release, BRFSS 2023, place-level) 1, above Louisiana's own 39.9% state rate 3, itself one of the highest in the country. Caddo Parish tracks almost identically at 42.2% 2, unsurprising since Shreveport holds roughly 78% of the parish's population (176,578 of 224,893, Census PEP Vintage 2024) 4.
The city sits in a 383,269-person metro, with 8% uninsured and a median household income of $48,699 56. The parish itself is shrinking, 224,893 in 2024 against 237,823 in 2020, while Bossier Parish, the metro's other half, grows (131,102 against 128,764 over the same period) 4.
Shreveport carries no active city-specific HPSA polygon — every historic Shreveport-only geographic HPSA (e.g. 'Low Income – Central Shreveport,' 'North Caddo') was withdrawn between 2000 and 2012. Current designations sit at the parish and facility level. HRSA's Primary Care file (checked 8/28/2026) shows 'LI-Caddo Parish' as a Designated Low-Income Population HPSA (ID 1225195141, score 14, PC MCTA score 17, designated 9/11/2025), covering 99,319 low-income residents — roughly 44% of the parish's ~226,000 people. Two Shreveport FQHCs carry their own facility-level Primary Care HPSA scores: David Raines Community Health Center (score 19, PC MCTA 20) and CASES — the Council for the Advancement of Social Services and Education (score 22, PC MCTA 23). Mental Health HPSAs mirror this: LI-Caddo Parish is a Designated psychiatrist-shortage HPSA (score 21, designated 3/3/2022, same 99,319 population), with David Raines (score 22) and CASES (score 17) again separately designated. Net: Shreveport's uninsured/low-income population routes through a parish with a formally recognized primary-care and psychiatry shortage, concentrated at its FQHC safety net.78
Specialist access
Shreveport has genuine academic specialist depth, unusual for a tier-2 city: Ochsner LSU Health Shreveport (LSU Health Sciences Center's academic medical center) runs a dedicated Endocrinology and Metabolism division across the hospital, its clinics, and the Overton-Brooks VA Medical Center. Named faculty include Dr. David Scarborough (clinical interests explicitly include obesity, alongside pituitary and thyroid disease), Dr. Rajini Yatavelli, and Dr. Kamal Bhusal (20+ years in practice). This makes Shreveport a real, citable referral hub for a multi-state catchment — north Louisiana, east Texas, south Arkansas — even though it sits inside a parish with a formally designated primary-care/psychiatry shortage for its low-income population.1617
Medicaid coverage note
Louisiana expanded Medicaid in 2016, and Medicaid already covers semaglutide and tirzepatide for diagnosed diabetes and certain liver-disease indications. New, and not yet active: Senate Bill 433 (2026 Regular Session), authored by Sen. Gerald Boudreaux, was signed into law as Act 898 on June 9, 2026 (R.S. 46:460.38). The statute directs the Louisiana Department of Health to cover FDA-approved weight-loss medications for adults with a BMI of 35–39 who have a qualifying comorbidity (prediabetes, hypertension, or cardiovascular disease), with no step-therapy requirement — press coverage names Ozempic, Wegovy, and Mounjaro as examples, and the Legislative Fiscal Office's own cost model uses 'GLP-1 medications' as shorthand for the covered category, though the statutory text itself does not name specific drugs. Critically, Act 898 is not self-executing: by its own terms it takes effect only once the Legislature separately passes a specific appropriation to fund it. The enrolled fiscal note (SLS 26RS 1370, dated June 1, 2026) assumes a January 1, 2027 target start and estimates roughly $10M in state cost for FY2027, rising to about $21.2M in FY2028 (~$102.7M over five years) — the Fiscal Office states it 'is unable to corroborate' the Department of Health's own estimates. As of this page's last review (8/28/2026), that funding had not yet been confirmed, so this benefit is signed into law but not yet active — describe it as such, never as current coverage.20
Louisiana's Medicaid GLP-1 law: signed, not yet active
Louisiana expanded Medicaid in 2016, and Medicaid already covers semaglutide and tirzepatide for diagnosed diabetes and certain liver-disease indications. New, and not yet active: Senate Bill 433 (2026 Regular Session), authored by Sen. Gerald Boudreaux, was signed into law as Act 898 on June 9, 2026 (R.S. 46:460.38) 20.
The statute directs the Louisiana Department of Health to cover FDA-approved weight-loss medications for adults with a BMI of 35-39 who have a qualifying comorbidity (prediabetes, hypertension, or cardiovascular disease), with no step-therapy requirement. Press coverage names Ozempic, Wegovy, and Mounjaro as examples 1819, and the Legislative Fiscal Office's cost model uses "GLP-1 medications" as shorthand for the covered category, though the statutory text itself does not name specific drugs.
Critically, Act 898 is not self-executing: by its own terms it takes effect only once the Legislature separately passes a specific appropriation to fund it. The enrolled fiscal note (SLS 26RS 1370, dated June 1, 2026) is the primary document on that point 20. For a Shreveport resident today, the honest answer is not yet.
What GLP-1 care costs in Shreveport today
Six Shreveport clinics were checked on 8/28/2026 and not one publishes an actual monthly dollar figure for semaglutide or tirzepatide. SemaShape's own pricing page claims to "hide nothing about pricing" while listing zero dollar amounts and directing visitors to text a phone number 12. The Wall Center's Jade MediSpa offers "weekly, monthly, and 6-month plans... contact us for a personalized quote" 14, RevIV's weight-loss page doesn't name GLP-1s at all 13, and Pretty Special Medspa's service page publishes no figure either 15.
The only real numbers in town are adjacent fees, and they are not drug prices. Shreveport Direct Care publishes a $109/month DPC membership ($147/month with three home visits a year, extra visits $100 each, and a $500/month "Never Come In" tier), plus a $250 one-time adult registration fee capped at $500 per family, and a separate Weight Management Program at $1,200 for the first six months then $775 per six-month period after, covering dietician visits, small-group sessions, meal planning, and body-composition testing. Its own language: "Basic weight management services are included in your membership... medications are not included" 910. aLine Health publishes a $175 initial consultation plus first labs and says medication pricing "starts at $99 per month for oral options," which are non-GLP-1 alternatives such as Contrave; no monthly dollar price for a GLP-1 itself is published 11.
Astra's national price is $68/month for semaglutide and $118/month for tirzepatide, both 12-month plans, the same in Shreveport as everywhere, every dose, flat.
A real specialist, a real shortage
Shreveport has genuine academic specialist depth, unusual for a tier-2 city: Ochsner LSU Health Shreveport, LSU Health Sciences Center's academic medical center, runs a dedicated Endocrinology and Metabolism division across the hospital, its clinics, and the Overton-Brooks VA Medical Center. Named faculty include Dr. David Scarborough, whose clinical interests explicitly include obesity alongside pituitary and thyroid disease, Dr. Rajini Yatavelli, and Dr. Kamal Bhusal, 20+ years in practice 1617. That makes the city a citable referral hub for a multi-state catchment across north Louisiana, east Texas, and south Arkansas.
It sits inside a parish with a formally designated shortage. Every historic Shreveport-only geographic HPSA ("Low Income - Central Shreveport," "North Caddo") was withdrawn between 2000 and 2012; current designations are parish- and facility-level. HRSA's Primary Care file (checked 8/28/2026) shows "LI-Caddo Parish" as a Designated Low-Income Population HPSA (ID 1225195141, score 14, PC MCTA score 17, designated 9/11/2025) covering 99,319 low-income residents, roughly 44% of the parish's ~226,000 people. David Raines Community Health Center (score 19, PC MCTA 20) and CASES, the Council for the Advancement of Social Services and Education (score 22, PC MCTA 23), carry their own facility-level scores. Mental Health mirrors it: LI-Caddo Parish is a Designated psychiatrist-shortage HPSA (score 21, designated 3/3/2022, same 99,319 population), with David Raines at 22 and CASES at 17 78.
Telehealth reaches that same population without requiring a slot at an already-stretched safety net or a drive to a clinic that won't quote a price over the phone. See the Louisiana GLP-1 overview for statewide context.
Astra treats patients in Louisiana through state-licensed physicians.
Local options
Shreveport Direct Care (Direct Primary Care) — Base DPC membership published at $109/month ($147/month with 3 home visits/year, extra visits $100 each; $500/month 'Never Come In' tier), plus a $250 one-time adult registration fee capped at $500/family. A separate Weight Management Program is priced at $1,200 for the first 6 months, then $775 per 6-month period after — covering dietician visits, small-group sessions, meal planning, and body-composition testing. The site's own language: 'Basic weight management services are included in your membership... medications are not included.' No dollar figure for semaglutide or tirzepatide itself is published anywhere on the site. https://www.shreveportdirectcare.com/membership(checked 2026-08-28)
aLine Health Direct Primary Care — Publishes an initial medical consultation plus first set of labs at $175, and states medication pricing 'starts at $99 per month for oral options' (non-GLP-1 alternatives such as Contrave). GLP-1s (Wegovy/Zepbound) are described as available through the DPC membership for patients with diabetes or complex needs, but no monthly dollar price for the GLP-1 medication itself is published. https://www.alinehealthdpc.com/medical-weight-loss-shreveport-la/(checked 2026-08-28)
SemaShape Weight Loss Clinic, RevIV Health & Wellness, The Wall Center (Jade MediSpa), and Pretty Special Medspa — All four confirmed Shreveport clinics offer semaglutide and/or tirzepatide, and none publishes an actual dollar figure on its own site. SemaShape's pricing page claims to 'hide nothing about pricing' yet lists zero dollar amounts and directs visitors to text a phone number. Jade MediSpa/The Wall Center offers 'weekly, monthly, and 6-month plans... contact us for a personalized quote.' RevIV's weight-loss page doesn't name GLP-1s at all. Pretty Special Medspa's service page has no pricing and directs visitors to call or book a consult. Core local-market finding: Shreveport's retail GLP-1 market is price-opaque across every clinic checked. https://semashape.com/pricing(checked 2026-08-28)
Frequently asked questions
Is Astra cheaper in Shreveport than a local clinic?
There's no honest side-by-side to give: of six Shreveport clinics and med-spas checked in August 2026 (SemaShape, RevIV Health & Wellness, The Wall Center/Jade MediSpa, Pretty Special Medspa, aLine Health DPC, and Shreveport Direct Care), not one publishes an actual monthly dollar price for semaglutide or tirzepatide on its own website — every one directs you to call, text, or book a consult for a quote. Astra's price is the only one in the market anyone can actually check without picking up the phone: $68/month for semaglutide and $118/month for tirzepatide, both on 12-month plans, the same price in Shreveport as everywhere else.
How much does Ozempic, Wegovy, or Mounjaro cost in Shreveport, LA?
No clinic in Shreveport publishes that number. The closest published figures are adjacent membership or program fees, not drug costs: Shreveport Direct Care's $109/month direct-primary-care membership (medications billed separately) or its own $1,200-then-$775-per-6-months weight-management program, and aLine Health's $99/month floor for oral (non-GLP-1) medications plus a $175 initial consult. Astra publishes its GLP-1 price directly: $68/month for semaglutide and $118/month for tirzepatide, both on 12-month plans, everywhere it operates.
Does Louisiana Medicaid cover GLP-1 weight-loss medication?
Not yet, though a law is on the books. Louisiana's Act 898 (Senate Bill 433, signed June 9, 2026) directs the state to cover FDA-approved weight-loss medications for adults with a BMI of 35–39 and a qualifying condition such as prediabetes or hypertension. But the law is not self-executing — it takes effect only once the Legislature separately appropriates the roughly $10–21 million a year the state's own fiscal analysts estimate it will cost, targeting a January 1, 2027 start. That funding has not yet been confirmed, so the benefit is signed into law but not yet active. (Louisiana Medicaid does already cover semaglutide and tirzepatide for diagnosed diabetes and certain liver-disease indications.)
What is Shreveport's obesity rate compared to the rest of Louisiana?
43.1% of Shreveport adults have obesity (2023 BRFSS, via CDC PLACES place-level data) — above Louisiana's own state rate of 39.9%, itself one of the highest in the country. Caddo Parish, Shreveport's home county, tracks almost identically at 42.2%.
Is telehealth GLP-1 treatment available in Shreveport, Louisiana?
Yes. Astra is licensed and serves all 50 states, including Louisiana. Care is delivered entirely online — a licensed provider reviews your visit and, if appropriate, a licensed pharmacy ships your prescription — with no clinic visit required in Shreveport or anywhere else.
Louisiana Legislature — SB 433 (2026 RS), signed as Act 898 (6/9/2026), R.S. 46:460.38; enrolled fiscal note SLS 26RS 1370 (6/1/2026) and Résumé Digest. NOTE: exact bill/document deep link not captured this session — verify the specific legis.la.gov URL for SB433/26RS before publish — https://legis.la.gov/
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.